Belgium · Delayed Price · Currency is EUR Nyxoah Earnings Call Transcripts
Fiscal Year 2026
-
Genio's differentiated bilateral neuromodulation technology for sleep apnea is gaining traction in the U.S. and internationally, with strong clinical evidence, robust reimbursement, and a focused commercialization strategy. Recent CMS updates ensure reimbursement parity, and the company targets break-even at €150 million revenue with high gross margins.
-
A differentiated neurostimulation solution for sleep apnea is rapidly gaining traction in the U.S. following FDA approval, with strong clinical evidence, high patient satisfaction, and robust reimbursement. Strategic expansion and innovation are set to drive further growth.
Fiscal Year 2025
-
2025 saw transformative growth with FDA approval and U.S. launch, driving 122% revenue growth and strong Q4 results. U.S. net revenue is expected to grow 25% sequentially in early 2026, with expanding sales coverage and improving gross margins.
-
The session highlighted rapid U.S. launch progress, strong reimbursement and surgeon adoption, and a focused expansion strategy. Financial guidance and pipeline updates indicate confidence in long-term growth, with new clinical data and technology improvements expected to drive future margin gains.
-
Q3 2025 saw a 56% revenue increase to €2 million, driven by a successful U.S. Genio launch and strong physician uptake. Operating loss widened due to commercial investments, but new capital raised extends cash runway into 2027. U.S. and international growth expected to accelerate in Q4.
-
The U.S. launch targets high-volume accounts with a focused commercial team and strong early surgeon engagement. Reimbursement approvals are consistent, and future growth will be driven by innovation, Triple C label expansion, and next-gen technology. GLP-1s are seen as a market tailwind.
-
A next-generation OSA therapy using bilateral hypoglossal nerve stimulation has launched in the U.S. following strong clinical evidence and regulatory approval. The commercial strategy targets high-volume sites and both ENT and sleep physicians, with rapid expansion and reimbursement progress. Ongoing R&D aims to further differentiate the platform and expand indications.
-
Leadership outlined a US-focused launch for their FDA-approved sleep apnea device, emphasizing technology differentiation and a targeted commercialization strategy. Financials show increased investment in R&D and commercial operations, with sufficient cash runway and breakeven targeted at lower volumes.
-
FDA approval of Genio system enables U.S. launch, driving 73.8% revenue growth year-over-year. Early commercial traction is strong, with over 100 physicians trained and multiple account approvals, while operating loss increased due to U.S. investments.
-
FDA approval for Genio system is expected in Q2 2025, with U.S. commercial launch preparations well underway. Q1 2025 revenue declined slightly year-over-year due to market softness and deferred purchases, while operating loss increased from U.S. investments. Cash runway extends into Q2 2026.
Fiscal Year 2024
-
2024 saw strong clinical and commercial progress, with Genio's DREAM study meeting all endpoints and international expansion continuing. FDA approval is expected by March 2025, with a U.S. launch and payer coverage ramping up through the year.
-
The company is nearing FDA approval for its bilateral neuromodulation implant for sleep apnea, with strong clinical data and a differentiated safety profile. U.S. launch is planned with a focused sales force, scalable strategy, and anticipated rapid payer coverage. Cash runway extends to mid-2026.
-
DREAM study met all endpoints, supporting Genio's U.S. launch, with FDA approval now expected in Q1 2025. Commercial investments increased losses, but a strengthened balance sheet extends the cash runway to mid-2026. U.S. strategy targets high-volume accounts and leverages German market success.
-
The company is preparing for a U.S. launch following strong DREAM trial results and anticipates FDA approval before year-end. Focused on expanding treatment options for OSA, it targets top-tier sites and plans label expansion for CCC patients by mid-2026.
-
Genio's bilateral hypoglossal nerve stimulation technology targets a large, under-served sleep apnea market, with pivotal clinical data supporting efficacy and safety. U.S. commercialization is set for year-end, focusing on high-volume centers, while European experience validates market acceptance and reimbursement parity.
-
Strong DREAM study results and a completed PMA submission position for potential FDA approval by late 2024. H1 2024 European sales rose 29% year-over-year, and over €85 million in new capital extends the cash runway into mid-2026. Genio's differentiated technology and scalable U.S. launch plan target rapid market expansion.
-
A disruptive neuromodulation solution for obstructive sleep apnea is set to enter the U.S. market, targeting FDA approval and commercial launch by year-end. Strong clinical results, a unique technology platform, and robust financial backing position the company for rapid growth and market share gains.